Evidence map›Paper›PMID 39516502›Full record

ArticleScientific reports2024

Alternative production of pro-death Bax∆2 protein via ribosomal frameshift in Alzheimer's disease.

Qi Yao, Adriana Mañas, Evan Beatty, Anne Caroline Mascarenhas Dos Santos, Yi Zhou, Oscar Juárez, Hui Chen, Jialing Xiang

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qi YaoDepartment of Biology, Illinois Institute of Technology, 3101 South Dearborn Street, Chicago, IL, 60616, USA.
Adriana MañasTranslational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy, IdiPAZ Research Center, University Hospital of La Paz, Madrid, Spain.
Evan BeattyDepartment of Biology, Illinois Institute of Technology, 3101 South Dearborn Street, Chicago, IL, 60616, USA.
Anne Caroline Mascarenhas Dos SantosDepartment of Biology, Illinois Institute of Technology, 3101 South Dearborn Street, Chicago, IL, 60616, USA.
Yi ZhouDepartment of Biology, Illinois Institute of Technology, 3101 South Dearborn Street, Chicago, IL, 60616, USA.
Oscar JuárezDepartment of Biology, Illinois Institute of Technology, 3101 South Dearborn Street, Chicago, IL, 60616, USA.
Hui ChenMass Spectrometer Core, University of Illinois at Chicago, Chicago, IL, 60612, USA.
Jialing XiangDepartment of Biology, Illinois Institute of Technology, 3101 South Dearborn Street, Chicago, IL, 60616, USA. xiang@iit.edu.

Funding

SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1991 to 2020
$49.1M
EPIDEMIOLOGY OF NEURAL RESERVE AND NEUROBIOLOGY IN AGINGR01AG017917 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2001 to 2023
$43.3M
Rush Alzheimer's Disease Research CenterP30AG072975 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI Lisa L Barnes, Julie A. Schneider · 2021 to 2026
$24.7M
RISK FACTORS, PATHOLOGY, AND CLINICAL EXPRESSIONS OF ADR01AG015819 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1998 to 2024
$21.4M
Multi-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targetsU01AG061356 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2018 to 2022
$13.7M
Pathway discovery, validation and compound identification for Alzheimer's disease - SupplementU01AG046152 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2013 to 2017
$13.6M
Acquisition of a Q-Exactive HF Mass SpectrometerS10OD027016 · OD · UNIVERSITY OF ILLINOIS AT CHICAGO · PI COLOGNA, STEPHANIE M · 2019 to 2019
$600k
NIA NIH HHS P30 AG010161NIA NIH HHS P30 AG072975NIA NIH HHS R01 AG015819NIA NIH HHS R01 AG017917NIA NIH HHS U01 AG046152NIA NIH HHS U01 AG061356NIH HHS S10 OD027016
6 · The paper itself

Abstract

Pro-death Bax family member, Bax∆2, forms protein aggregates in Alzheimer's disease neurons and causes stress granule-mediated neuronal death. Production of Bax∆2 originated from two events: alternative splicing of Bax exon 2 and a microsatellite mutation (a deletion from poly guanines, G8 to G7). Each event alone leads to a reading frameshift and premature termination. While Bax exon 2 alternative splicing is common in Alzheimer's brains, the G7 mutation is not, which is inconsistent with the high Bax∆2 protein levels detected in clinical samples. Here, we report an alternative mechanism to produce Bax∆2 protein in the absence of the G7 mutation. Using dual-tag systems, we showed that a ribosomal frameshift (RFS) can compensate the lack of G7 mutation in translating Bax∆2 protein. Intriguingly, the microsatellite poly G repeat is neither essential nor the site for the RFS. However, disruption of the poly G sequence impaired the RFS, potentially due to alteration of the local RNA structure. Using immunoprecipitation-mass spectrometry, we pinpointed the RFS site at 15 base pairs upstream of the microsatellite. These results uncover an alternative mechanism for generating functional Bax∆2-subfamily isoforms, highlighting the production plasticity of Bax family isoforms and unveiling potential new therapeutic targets for Alzheimer's disease.

Indexed as

Alzheimer Diseasebcl-2-Associated X ProteinFrameshift MutationAlternative SplicingExonsHumansMicrosatellite RepeatsRibosomesBAX protein, humanbcl-2-Associated X ProteinAlzheimer’s diseaseBaxBax∆2Cell deathMicrosatelliteRibosomal frameshift

Identifiers

PMID39516502
PMCPMC11549088

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.